Hims & Hers Health (NYSE:HIMS) CFO Oluyemi Okupe Sells 9,388 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 9,388 shares of Hims & Hers Health stock in a transaction on Monday, August 17th. The shares were sold at an average price of $27.89, for a total transaction of $261,831.32. Following the completion of the sale, the chief financial officer directly owned 264,117 shares of the company’s stock, valued at approximately $7,366,223.13. This trade represents a 3.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Oluyemi Okupe also recently made the following trade(s):

• On Thursday, June 18th, Oluyemi Okupe sold 55,383 shares of Hims & Hers Health stock. The stock was sold at an average price of $35.09, for a total transaction of $1,943,389.47.
• On Monday, July 6th, Oluyemi Okupe sold 7,163 shares of Hims & Hers Health stock. The shares were sold at an average price of $36.49, for a total value of $261,377.87.
• On Monday, June 22nd, Oluyemi Okupe sold 18,197 shares of Hims & Hers Health stock. The shares were sold at an average price of $34.03, for a total value of $619,243.91.

Hims & Hers Health Stock Down 4.1%

HIMS stock opened at $27.43 on Wednesday. The stock’s 50 day simple moving average is $32.10 and its 200 day simple moving average is $26.05. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $65.30. The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93. The company has a market cap of $6.40 billion, a P/E ratio of -43.53 and a beta of 2.40.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The firm had revenue of $753.21 million during the quarter, compared to the consensus estimate of $698.90 million. Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The firm’s revenue was up 38.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.17 EPS. On average, research analysts expect that Hims & Hers Health, Inc. will post -0.05 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Hims & Hers Health by 7.2% in the fourth quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after purchasing an additional 1,407,651 shares during the last quarter. State Street Corp increased its position in Hims & Hers Health by 1.8% in the fourth quarter. State Street Corp now owns 7,305,525 shares of the company’s stock worth $237,210,000 after buying an additional 132,311 shares during the last quarter. Geode Capital Management LLC increased its position in Hims & Hers Health by 12.4% in the fourth quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock worth $183,485,000 after buying an additional 608,950 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Hims & Hers Health by 194.4% in the first quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock valued at $90,465,000 after buying an additional 2,877,550 shares during the period. Finally, Invesco Ltd. raised its stake in shares of Hims & Hers Health by 62.7% in the third quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock valued at $235,525,000 after buying an additional 1,600,004 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: CEO Andrew Dudum defended Hims & Hers against the FTC’s allegations, arguing that the agency misunderstands the company’s data-sharing and subscription practices. He also said compounded GLP-1 medications helped lower treatment costs, potentially supporting the company’s broader affordability strategy. Hims & Hers CEO says FTC lawsuit misunderstands how the company works
• Positive Sentiment: An analysis highlighted the Eucalyptus deal as a potential way for Hims & Hers to enter new markets and broaden its international or product reach, offering a possible growth catalyst. Hims & Hers: Eucalyptus Deal Unlocks New Markets
• Neutral Sentiment: Dudum’s CNBC interview also addressed artificial intelligence, the transition from compounded to branded GLP-1 drugs and efforts to reduce healthcare costs. These initiatives could influence the company’s long-term strategy, but they do not resolve the immediate regulatory concerns. Watch CNBC’s full interview with Hims & Hers CEO Andrew Dudum
• Neutral Sentiment: Analysts’ questions following the second-quarter earnings call indicate continued investor scrutiny of growth, profitability and the company’s GLP-1 strategy. The prior quarter featured strong revenue growth but a larger-than-expected loss, increasing the importance of execution. 5 Revealing Analyst Questions From Hims & Hers Health’s Q2 Earnings Call
• Negative Sentiment: The FTC lawsuit alleges improper business practices involving privacy and billing. The news previously triggered a sharp selloff, and shareholder-law-firm investigations by Hagens Berman, Kessler Topaz and Kaplan Fox are adding legal, compliance and potential securities-liability risks. FTC lawsuit and Hagens Berman investigation
• Negative Sentiment: CFO Oluyemi Okupe sold shares, including 9,388 shares on August 17. However, both disclosed sales were made under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards, making them a limited bearish signal rather than clear evidence of deteriorating confidence. SEC insider transaction filing

Analysts Set New Price Targets

A number of analysts have commented on the stock. Citigroup decreased their price target on shares of Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating for the company in a research note on Tuesday, August 11th. Wall Street Zen raised shares of Hims & Hers Health from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reiterated a “sell (d)” rating on shares of Hims & Hers Health in a report on Friday, August 7th. Canaccord Genuity Group boosted their target price on shares of Hims & Hers Health from $32.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Finally, Needham & Company LLC upped their target price on shares of Hims & Hers Health from $35.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Four research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $32.43.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.